Ligand Pharmaceuticals

Quarterly Financials

Values in thousands 2025-06-30 2025-03-31 2024-12-31 2024-09-30
Revenue
$47,627
$45,333
$42,812
$51,812
Gross Profit
46,808
40,484
39,975
39,317
EBITDA
9,720
-40,543
-29,690
3,396
EBIT
-49,313
-38,317
-5,598
Net Income
4,847
-42,451
-31,088
-7,172
Net Change In Cash
47,627
45,333
42,812
51,812
Free Cash Flow
15,585
-25,659
27,759
22,289
Cash
245,020
47,989
72,307
63,619
Basic Shares
19,259
19,191
18,974
18,419

Annual Financials

Values in thousands 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Revenue
$167,133
$131,314
$196,245
$277,133
Gross Profit
156,059
96,265
143,418
214,957
EBITDA
40,794
100,837
54,407
133,161
EBIT
5,555
64,316
11,013
91,824
Net Income
-4,032
52,154
-5,219
57,138
Net Change In Cash
167,133
131,314
196,245
277,133
Cost of Revenue
-28,440
Free Cash Flow
95,226
-4,272
119,927
70,037
Cash
72,307
22,954
45
19,522
Basic Shares
18,290
17,757
16,868
17,246

Earnings Calls

Quarter EPS
2025-09-30
$0
2025-06-30
$1.60
2025-03-31
$1.33
2024-12-31
$1.27